In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
|Videos|March 2, 2017
Charles Kamen on Cancer-Related Distress in LGBT Patients
Author(s)Charles Kamen, PhD
Charles Kamen, PhD, University of Rochester Medical Center, discusses the disparity that LGBT patients face when it comes to cancer-related stress and depression.
Advertisement
Charles Kamen, PhD, University of Rochester Medical Center, discusses the disparity in cancer-related distress that LGBT patients can experience.
Overall, LGBT patients with cancer have a higher level of anxiety than other patients. Kamen hypothesizes this is because LGBT patients have a higher baseline anxiety in their daily life. When those patients are diagnosed with cancer, any anxiety gets added to that baseline.
Advertisement
Related to this article
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.
ASTRO 2026 presenter Kayla Kafka-Peterson details an Adapt-Adopt-Build model to bridge global brachytherapy nursing gaps and standardize perioperative care.
At ASTRO 2026, Dr. Nitin Ohri details additive versus synergistic toxicities when combining radiation with novel systemic therapies in clinical trials.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
2
IMS 2026: Beth Faiman Talks New Definition of Myeloma Cure and More
3
FDA Approves Maintenance Tucatinib for Advanced HER2+ Breast Cancer
4
Daily Symptom Shifts Linked to Quality of Life in Metastatic Breast Cancer
5